Endo Pharmaceuticals, Inc. v. Teva Pharmaceuticals USA, Inc., No. 2017-1240 (Fed. Cir. Mar. 28, 2019)
USA April 23 2019
The patentee sued for infringement of a patent directed to methods of pain treatment for patients with poor kidney function. Specifically, the patent claimed that less of the drug was necessary to treat pain in patients with poor kidney function than for patients with normal kidney function. The magistrate judge issued a report and recommendation finding that the claims were ineligible for patenting, and the district court adopted the magistrate judge's report and recommendation. On appeal, the Federal Circuit reversed and found that the claims covered patent-eligible subject matter.
Applying the Supreme Court's two-step framework from Alice, the court found that the claims were directed to patent-eligible subject matter. The court had found claims to a method of treatment with a drug patent-eligible in Vanda Pharmaceuticals Inc. v. West-Ward Pharmaceuticals Int'l Ltd. The court found these claims "legally indistinguishable" from the claims in Vanda. The court explained that the claims in this case require administering the compound to a patient who had specific characteristics, to treat a specific condition, and using a specific compound, and were patent-eligible.
The court further found that the claims in this case differed from the claims in Mayo Collaborative Servs. v. Prometheus Labs. In Mayo, the claims were not directed at treating a specific disease or at treating a patient based on certain test results. In this case, the drug is administered based on test results regarding kidney functioning. Further, the inventor in this case did not claim merely the relationship between the drug and patients with poor kidney function. Instead, the inventor claimed a method of treatment by lowering the drug dose for patients with poor kidney function, which was patent-eligible.
A copy of the opinion can be found here
Winston & Strawn LLP - Kathleen Barry
SEC renews focus on insider trading in private company stock *
Conspiracy Claims Against Egg Producers Laid to Rest by Jury *
Code42 Report Finds Companies Are Not Sufficiently Combatting Risk of Insider Data Threats *
Discretion and Performance-Based Pay under the New 162(m) Proposed Regulations *
Court Holds that "Consultant" Was a Section 16 Officer *
How effective are sexual harassment and gender discrimination laws?
Endo Pharmaceuticals Inc. v. Teva Pharmaceuticals USA, Inc. *
Federal Circuit Holds That Claims Directed to Methods of Treating Pain in a Renally Impaired Patient Are Patent-Eligible Under Section 101 *
Pain Treatment, Kidney Failure, and 101 *
USPTO explains Federal Court ruling on method of treatment patents * - Global
Personalised diagnostic method claims considered unpatentable laws of nature * - Australia
Australia sets its own course on the patentability of biotechnology * - Australia
Nadia Martel
Senior Legal Counsel
C2MI
" I am very pleased with the content of the Lexology newsfeeds. They are a centralized way of getting legal related updates from many jurisdictions and a great way to stay informed with a minimal time commitment."